2000
Salgado R, Benoy I, Weytjens R, Vermeulen PB, Dirix LY. Serum
vascular endothelial growth factor load and interleukin-6 in cancer
patients - reply. Br J Cancer. 2000 Jun;82(11):1896.
Vermeulen P, Hoekx L, Colpaert C, Wyndaele JJ, Van Marck E.
Biphasic sarcomatoid carcinoma (carcinosarcoma) of the renal pelvis
with heterologous chondrogenic differentiation.Virchows Arch. 2000
Aug;437(2):194-7.
1999
Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E.
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and
-2, and TGF beta expression. J Pathol. 1999 Sep;189(1):72-8.
Lauwers P, Hubens G, Hendriks J, Vermeulen P, Schuerwegh A, Stevens
WJ, De Clerck LS, Dirix L, Van Marck E, Hubens A, Eyskens E.
Effects of suramin on anastomotic colon tumors in a rat model. Eur
Surg Res. 1999;31(4):347-56.
Dirix LY, Van Oosterom AT. Soft tissue sarcoma in adults. Curr Opin
Oncol. 1999 Jul;11(4):285-95. Review.
Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E,
Dirix LY. Platelet number and interleukin-6 correlate with VEGF but
not with bFGF serum levels of advanced cancer patients. Br J
Cancer. 1999 May;80(5-6):892-7.
Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E,
Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY,
Gion M. Clinical relevance of vascular endothelial growth factor
and thymidine phosphorylase in patients with node-positive breast
cancer treated with either adjuvant chemotherapy or hormone
therapy. Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11.
Vermeulen PB, Salven P, Benoy I, Gasparini G, Dirix LY. Blood
platelets and serum VEGF in cancer patients. Br J Cancer. 1999
Jan;79(2):370-3.
Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J,
Lardon F, Van Marck E, Hubens G, Dirix LY. Prospective study of
intratumoral microvessel density, p53 expression and survival in
colorectal cancer. Br J Cancer. 1999 Jan;79(2):316-22.
1998
Benoy I, Vermeulen P, Wuyts H, Dirix L.Vascular endothelial cell
growth factor (VEGF) serum concentrations change according to the
phase of the menstrual cycle. Eur J Cancer. 1998
Jul;34(8):1298-9.
Tjalma W, Van Marck E, Weyler J, Dirix L, Van Daele A, Goovaerts G,
Albertyn G, van Dam P. Quantification and prognostic relevance of
angiogenic parameters in invasive cervical cancer. Br J Cancer.
1998 Jul;78(2):170-4.
Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix
LY, Ranieri G, Miceli R, Cheresh DA. Vascular integrin
alpha(v)beta3: a new prognostic indicator in breast cancer. Clin
Cancer Res. 1998 Nov;4(11):2625-34.
1997
Dirix LY, Libura M, Libura J, Vermeulen PB, De Bruijn EA, Van
Oosterom AT. In vitro toxicity studies with mitomycins and
bleomycin on endothelial cells. Anticancer Drugs. 1997
Oct;8(9):859-68.
Vermeulen PB, Dirix LY, Martin M, Lemmens J, Van Oosterom AT. Serum
basic fibroblast growth factor and vascular endothelial growth
factor in metastatic renal cell carcinoma treated with interferon
alfa-2b. J Natl Cancer Inst. 1997 Sep 3;89(17):1316-7.
Dirix LY, Vermeulen P, De Wever I, Van Oosterom AT. Soft tissue
sarcoma in adults. Curr Opin Oncol. 1997 Jul;9(4):348-59.
Review.
Vermeulen PB, Dirix LY, Libura J, Vanhoolst IF, Van Marck E, Van
Oosterom AT. Correlation of the fractions of proliferating tumor
and endothelial cells in breast and colorectal adenocarcinoma is
independent of tumor histiotype and microvessel density. Microvasc
Res. 1997 Jul;54(1):88-92.
Kumar-Singh S, Vermeulen PB, Weyler J, Segers K, Weyn B, Van Daele
A, Dirix LY, Van Oosterom AT, Van Marck E. Evaluation of tumour
angiogenesis as a prognostic marker in malignant mesothelioma. J
Pathol. 1997 Jun;182(2):211-6.
Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C,
Martin M, Van Oosterom AT. Elevated levels of the angiogenic
cytokines basic fibroblast growth factor and vascular endothelial
growth factor in sera of cancer patients. Br J Cancer.
1997;76(2):238-43.
Vermeulen PB, Libura M, Libura J, O'Neill PJ, van Dam P, Van Marck
E, Van Oosterom AT, Dirix LY. Influence of investigator experience
and microscopic field size on microvessel density in node-negative
breast carcinoma. Breast Cancer Res Treat. 1997
Jan;42(2):165-72.
1996
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P,
Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification
of angiogenesis in solid human tumours: an international consensus
on the methodology and criteria of evaluation. Eur J Cancer. 1996
Dec;32A(14):2474-84. Review.
Vermeulen PB, Dirix LY, Van Marck E, Van Oosterom AT. High
endothelial cell proliferation index and high microvessel density
in vascular hotspots suggest an active angiogenic process in human
colorectal adenocarcinomas. Angiogenesis Group. Br J Cancer. 1996
Nov;74(9):1506-7.
Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C,
Van Oosterom AT. Serum basic fibroblast growth factor and vascular
endothelial growth factor and tumour growth kinetics in advanced
colorectal cancer. Ann Oncol. 1996 Oct;7(8):843-8.
Dirix LY, Vermeulen PB, Van Oosterom AT, Gasparini G. Microvascular
count and prognosis in colorectal cancer. J Clin Oncol. 1996
Aug;14(8):2400-3.
Hubens G, Pauwels M, Hubens A, Vermeulen P, Van Marck E, Eyskens E.
The influence of a pneumoperitoneum on the peritoneal implantation
of free intraperitoneal colon cancer cells. Surg Endosc. 1996
Aug;10(8):809-12.
Vermeulen PB, Roland L, Mertens V, Van Marck E, De Bruijn EA, Van
Oosterom AT, Dirix LY. Correlation of intratumoral microvessel
density and p53 protein overexpression in human colorectal
adenocarcinoma. Microvasc Res. 1996 Mar;51(2):164-74.
Dirix LY, Vermeulen PB, Fierens H, De Schepper B, Corthouts B, Van
Oosterom AT. Long-term results of continuous treatment with
recombinant interferon-alpha in patients with metastatic carcinoid
tumors--an antiangiogenic effect? Anticancer Drugs. 1996
Feb;7(2):175-81.
1995
Vermeulen PB, Libura J, Libura M, Hellemans PW, Van Marck E, Van
Oosterom AT, Dirix LY. Re: Tumor angiogenesis as a prognostic assay
for invasive ductal breast carcinoma. J Natl Cancer Inst. 1995 Dec
6;87(23):1797-8; author reply 1801-2.
Vermeulen PB, Dirix LY, Pelgrims G, Van Oosterom AT.
5-fluorouracil/leucovorin/interferon alpha-2a in patients with
advanced colorectal cancer. Cancer. 1995 Aug 1;76(3):528-30.
Vermeulen PB, Verhoeven D, Fierens H, Hubens G, Goovaerts G, Van
Marck E, De Bruijn EA, Van Oosterom AT, Dirix LY. Microvessel
quantification in primary colorectal carcinoma: an
immunohistochemical study. Br J Cancer. 1995 Feb;71(2):340-3.
Vermeulen PB, Verhoeven D, Hubens G, Van Marck E, Goovaerts G,
Huyghe M, De Bruijn EA, Van Oosterom AT, Dirix LY. Microvessel
density, endothelial cell proliferation and tumour cell
proliferation in human colorectal adenocarcinomas. Ann Oncol. 1995
Jan;6(1):59-64.